Niagen Bioscience, Inc. (NAGE) vs Zentalis Pharmaceuticals, Inc. (ZNTL)

Niagen Bioscience, Inc. and Zentalis Pharmaceuticals, Inc. are both Biotechnology companies. Niagen Bioscience, Inc. and Zentalis Pharmaceuticals, Inc. are of similar size ($212.1M and $204.2M). Zentalis Pharmaceuticals, Inc. has negative trailing earnings, so its P/E is not meaningful; Niagen Bioscience, Inc. trades at 12.5×. Niagen Bioscience, Inc. has the higher net margin (12.4% vs 0.00%) and the higher return on invested capital (42.0% vs 0.00%). Across the 14 metrics below, Niagen Bioscience, Inc. leads on 12 and Zentalis Pharmaceuticals, Inc. on 2.

Valuation

Metric NAGE ZNTL Biotechnology median
P/E 12.45 n/m 8.50
P/S 1.53 n/m 9.71
P/B 2.39 1.06 2.13
Price to free cash flow 17.24 n/m 20.82
EV/EBITDA 11.46 0.15 0.64
EV/Sales 1.03 n/m 9.21
Earnings yield 8.03% (91.55%) (33.15%)
Free cash flow yield 5.80% (84.25%) (25.50%)

Profitability

Metric NAGE ZNTL Biotechnology median
Gross margin 64.24% 0.00% 65.16%
Operating margin 8.21% 0.00% 0.00%
Net margin 12.39% 0.00% 0.00%
Free cash flow margin 8.89% 0.00% 0.00%
Return on equity 21.80% (66.75%) (56.36%)
Return on assets 16.14% (49.22%) (48.04%)
Return on invested capital 41.95% 0.00% 0.00%

Growth

Metric NAGE ZNTL Biotechnology median
Revenue growth (TTM) 10.99% — 6.02%
EPS growth (last fiscal year) 81.82% 18.03% 30.26%
Revenue growth, 5-year CAGR 16.91% — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric NAGE ZNTL Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 6.50 4.82 4.72
Net debt to EBITDA (3.80) 1.59 0.96

Dividend

Metric NAGE ZNTL Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric NAGE ZNTL Biotechnology median
Market cap 204.15m 212.07m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack